Slide 1: Exchange filing cover letter for earnings presentation
May 18, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Bandra-Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai - 400 051, Maharashtra. Dalal Street, Mumbai – 400 001, Maharashtra. Symbol: STAR Scrip Code: 532531 Dear Sirs, Sub: Earnings Presentation for the qua
Slide 2: Q4 & FY26 Earnings Presentation
Q4 & FY26 Earnings Presentation May 18, 2026 Strides Pharma Science Limited Health where it matters
Slide 3: Safe Harbor
Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "p
Slide 4: Strides Delivers Strong Performance with FY26 EBITDA at ₹9,253m and Operational PAT at ₹5,181m
Strides Delivers Strong Performance with FY26 EBITDA at ₹9,253m and Operational PAT at ₹5,181m Operational PAT and Operational EPS Grew 50% YoY Board Recommends Dividend of ₹5 per share for FY26 FY26 FY25 YoY Change Strides continued to deliver strong performance across profitability, efficiency, an
Slide 5: Q4FY26 Revenue at ₹13,235m, Grew 11% YoY
Q4FY26 Revenue at ₹13,235m, Grew 11% YoY Q4FY26 Operational PAT at ₹1,357m and EPS at ₹14.7, Grew 20% YoY Q4FY26 Q4FY25 YoY Change Revenue Breakup (₹M) Revenue (₹m) 13,235 11,904 YoY 11.2% US Market Ex-US Markets Access Markets ₹ 310 Gross Margins (₹m) 7,872 6,914 13.9% ₹ 589 Gross Margin (%) 59
Slide 6: Sustained Growth Across P&L Metrics Over the Last 3 Years
Sustained Growth Across P&L Metrics Over the Last 3 Years Profitability Focus Delivers Superior PAT Performance, Outperforming Revenue and EBITDA growth Total Revenue (₹M) Gross Margin (₹M) EBITDA (₹M) Operational PAT (₹M) Gross Margin Gross Margin (%) EBITDA EBITDA (%) CAGR 12% CAGR 330% CAGR 1
Slide 7: Ex-US Market Registers a Strong Growth Over FY24-26
Ex-US Market Registers a Strong Growth Over FY24-26 Growth Across Regions in Ex-US Markets Offsets Decline in Access Market Revenue Composition (₹M) US Market (₹M) Ex-US Market (₹M) Access Market* (₹M) US ORM ORM Growth Market Growth Market Access Market 3% CAGR 11% CAGR 19% CAGR -34% 8% 6% 12%
Slide 8: US Market
US Market Health where it matters
Slide 9: FY26 US Revenue at $284m, Steady Despite New Entrants and Weak Flu Season
FY26 Revenue at $284m, Remained Steady Despite New Entrants in Recent Launches and Weak Flu Season in H2 Year-on-Year Comparison (₹/$M) Comments • FY26 revenue at $284m, reflects H2 seasonality headwinds YoY 2% • Launched 6 products in FY26 $291 $284 • Discontinued 9 products in FY26 that did not m
Slide 10: Ex-US Market
Ex-US Market Health where it matters
Slide 11: Ex-US Market Revenue at $254m, Grew 21% YoY
Ex-US Market Revenue at $254m, Grew 21% YoY Driven by Strong Performance Across Markets Year-on-Year Comparison (₹/$M) Comments Other Regulated Markets YoY 21% $254 • All regulated markets except US form part of the Other Regulated Markets $221 • Focus on ORM playing out in FY26 with revenue at $1
Slide 12: Financial Performance
Financial Performance Strong Financial Discipline Enabled Profitable Growth Health where it matters
Slide 13: Income Statement
Income Statement Income statement (₹M) Particulars Q4FY26 Q4FY25 YoY Q3FY26 QoQ FY26 FY25 YoY I. Revenue 13,235 11,904 11.2% 11,946 10.8% 48,587 45,653 6.4% II. Material Costs 5,362 4,989 4,629 19,587 19,799 III. Gross Margin (I- II) 7,872 6,914 13.9% 7,317 7.6% 29,000 25,854 12.2% Gross Margin % 59
Slide 14: Reported Net Debt at ₹14,365m with Net Debt/EBITDA of 1.55x
Reported Net Debt at ₹14,365m with a Net Debt/EBITDA of 1.55x, post Fx Impact of ₹1,115m Net Debt at ₹13,250m on Constant Currency, after Funding for ₹4,179m of Capex & Growth Initiatives Particulars (In ₹m) Mar’25 Mar’26 Finance cost (In ₹m) FY25 FY26 Working Capital Loans 11,364 9,476 Long Term Lo
Slide 15: Continued Steady Performance Across Key Metrics Despite External Headwinds
Continued Steady Performance Across Key Metrics, Despite Adverse Impact of External Headwinds Net Debt to Equity (x) Net Debt to EBITDA (x) Cash to Cash Cycle (Days) 0.98 3.47 129 124 117 0.59 1.90 0.46 1.55 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 Current Ratio (x) RoCE (%) Fixed Asset Turnover
Slide 16: Balance Sheet
Balance Sheet Strong Corporate Governance and Corporate Actions improved the Balance Sheet position Particulars (In ₹m) 31-Mar-24 31-Mar-25 31-Mar-26 Assets Net Tangible Assets ( including CWIP) 8,809 9,220 10,756 Right-of-use assets 895 695 782 Goodwill and Other Intangibles 10,565 11,145 13,941 In
Slide 17: Corporate Updates
Corporate Updates Health where it matters
Slide 18: Strengthening Executive Management on the Board
Strengthening Executive Management on the Board Leadership to Support Long-term Growth Strategy New Board Member - Executive Director Ramaraju PVS Expertise: ✓ Ramaraju is currently Chief Operating Officer (COO) of Strides, holds a master’s degree in Pharmaceutical Chemistry and has vast experience
Slide 19: Q4FY26 Earnings Call Details
Q4FY26 Earnings Call Details invites you to interact with the senior management on Q4FY26 Performance Click Here pre-register and join without the operator May 18, 2026 5:00 pm IST / 11:30 am GMT / 7:30 am EDT / 7:30 pm HKT ` Participants from the Management would be: Badree Komandur Vikesh Kumar Jo
Slide 20: Thank You
Health where it matters Thank You Youtube logo Images - Free Download on Freepik To know more: www.strides.com Investor-relations@strides.com Stay Connected © 2026 Strides Pharma All Rights Reserved. This presentation is intended solely for the use of the individual or entity to whom it is addressed